Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | STAT3 | P40763 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | MMP7 | P09237 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3064836 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2STAT3PPARGGAAALDH1A1 | |
| SCHEMBL7265141 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2STAT3PPARGGAAALDH1A1 | |
| SCHEMBL10572149 | 0.88 | CA12 (0.44) | STAT3PPARGGAAALDH1A1SLC1A3 | |
| SCHEMBL2325751 | 0.88 | CA12 (0.44) | STAT3PPARGGAAALDH1A1SLC1A3 | |
| SCHEMBL13433912 | 0.87 | KMT2A (0.40) | SMN1; SMN2STAT3PPARGGAAALDH1A1 | |
| SCHEMBL15669212 | 0.87 | PSIP1 (0.42) | SMN1; SMN2PPARGALDH1A1PPARA | |
| SCHEMBL2363971 | 0.86 | ALDH1A1 (0.46) | SMN1; SMN2STAT3GAAALDH1A1KMT2A | |
| SCHEMBL9306403 | 0.86 | KDM4E (0.44) | SMN1; SMN2STAT3PPARGGAAALDH1A1 | |
| SCHEMBL2328955 | 0.86 | KMT2A (0.46) | SMN1; SMN2STAT3GAAALDH1A1KMT2A | |
| SCHEMBL2328962 | 0.85 | PPARG (0.42) | SMN1; SMN2STAT3PPARGGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112409378-A | Tricyclic PI3K inhibitor compounds and methods of use thereof | 豪夫迈·罗氏有限公司 | 2021-02-26 | — | — | CN | disclosed |
| CN-108349996-B | Tricyclic PI3K inhibitor compounds and methods of use thereof | 豪夫迈·罗氏有限公司 | 2021-01-08 | — | — | CN | disclosed |
| US-8338621-B2 | Process for the preparation of 2-oxo-1-pyrrolidine derivatives | UCB S.A. (BE) | 2012-12-25 | — | — | US | disclosed |
| US-8008350-B2 | Biphenyloxyacetic acid derivatives for the treatment of respiratory disease | ASTRAZENECA AB (SE) | 2011-08-30 | — | — | US | disclosed |
| EP-2360160-A1 | Intermediates and their use for producing benzoxazine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-08-24 | — | — | EP | disclosed |
| EP-1806339-B1 | Process for the preparation of 2-oxo-1-pyrrolidine derivatives | UCB PHARMA SA (BE) | 2011-08-17 | — | — | EP | disclosed |
| US-20110152374-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | ASTRAZENECA AB (SE) | 2011-06-23 | — | — | US | disclosed |
| US-20080009638-A1 | PROCESS FOR THE PREPARATION OF 2-OXO-1-PYRROLIDINE DERIVATIVES | UCB S.A. (BE) | 2008-01-10 | — | — | US | disclosed |
| EP-1806339-A1 | Process for the preparation of 2-oxo-1-pyrrolidine derivatives | UCB, S.A. (BE) | 2007-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009638-A1 | PROCESS FOR THE PREPARATION OF 2-OXO-1-PYRROLIDINE DERIVATIVES | CYP2F1, CYP3A5, SULT1E1 | SMN1; SMN2 1757/4885STAT3 4539/4885PPARG 1888/4885 |
| US-20110152374-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | BPGM, PPARA, HPD | SMN1; SMN2 3079/4885STAT3 3574/4885PPARG 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.